ESMO 2017 Immuno-Oncology
Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma
Excellent news for patients who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented today by Dr Jeffrey Weber.
